Refractory aggressive B-cell lymphomas
Showing 1 - 25 of >10,000
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Completed
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +3 more
- Allogeneic Bone Marrow Transplantation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,
Suspended
- Burkitt Lymphoma
- +4 more
- Rituximab
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)
Recruiting
- Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- TEDD-R
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)
Not yet recruiting
- Lymphomas
- B-cell Lymphomas
- JV-213
- Leukapheresis
-
Houston, TexasThe University of Texas M D Anderson Cancer Center
Mar 6, 2023
Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)
Not yet recruiting
- Relapsed/Refractory Aggressive B-Cell Malignancies
- ONCT-808
- Bridging Therapy
- (no location specified)
Jan 19, 2023
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)
Recruiting
- B Cell Lymphoma
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- +5 more
- Belinostat
- +2 more
- (no location specified)
Dec 2, 2022
DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)
Completed
- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma
- Venetoclax
- +6 more
-
Boston, Massachusetts
- +5 more
Aug 23, 2022
Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)
Not yet recruiting
- Relapsed or Refractory T-cell Lymphomas
-
Sendai-shi, Miyagi, JapanLocal Institution - 0001
Sep 12, 2023
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas Trial (ATG-031)
Not yet recruiting
- Advanced Solid Tumors
- B-cell Non-Hodgkin Lymphomas
- (no location specified)
Aug 31, 2023
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease Trial in Chicago, Saint Louis (Romidepsin,
Completed
- Lymphoma, T-Cell, Cutaneous
- +3 more
- Romidepsin
- +4 more
-
Chicago, Illinois
- +1 more
Nov 16, 2020
DLBCL - Diffuse Large B Cell Lymphoma Trial in Italy
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
-
Bologna, Italy
- +12 more
Sep 4, 2023
Lymphoma, B-Cell, Lymphoma, T-Cell Trial in Nashville (STP938)
Recruiting
- Lymphoma, B-Cell
- Lymphoma, T-Cell
-
Nashville, TennesseeTennessee Oncology
Aug 3, 2022
Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Standard of Care
- JCAR017
-
Phoenix, Arizona
- +78 more
Jan 13, 2023
Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive
Active, not recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- fractionated first dose rituximab
-
Geneva, SwitzerlandUniversity Hospital Geneva
Apr 21, 2023
Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- infusion of JY231 injection
-
Guangzhou, Guangdong, ChinaGuangdong Second Provincial General Hospital
Sep 17, 2023